Clinical trials
Phase 2 Eczema trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Terminated | 11 |
| Recruiting | 8 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 4 |
| Asana BioSciences | 3 |
| Novartis Pharmaceuticals | 3 |
| ASLAN Pharmaceuticals | 2 |
| Aclaris Therapeutics, Inc. | 2 |
| Apollo Therapeutics Ltd | 2 |
| Eli Lilly and Company | 2 |
| Evelo Biosciences, Inc. | 2 |
| Forte Biosciences, Inc. | 2 |
| GlaxoSmithKline | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eczema | 70 |
| Dermatitis, Atopic | 66 |
| Dermatitis | 20 |
| Skin Diseases | 13 |
| Pruritus | 10 |
| Immune System Diseases | 7 |
| Skin Diseases, Eczematous | 4 |
| Food Hypersensitivity | 2 |
| Inflammation | 2 |
| Skin Diseases, Genetic | 2 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.